The global COPD and asthma devices market size reached US$ 45.7 Billion in 2023. Looking forward, the market is projected to reach US$ 69.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.77% during 2023-2032.
Chronic obstructive pulmonary disease (COPD) is an inflammatory disease that leads to obstructed airflow from the lungs. Its early symptoms include shortness of breath, wheezing, chest tightness, chronic cough with or without mucus, frequent cold, and throat soreness. On the other hand, asthma, also known as bronchial asthma, is a respiratory disorder that affects the airways in the lungs.
Its symptoms are shortness of breath, chest tightness, trouble sleeping, and coughing or wheezing attacks. These respiratory diseases are treated using various devices that help deliver inhaled medication. COPD and asthma devices, also known as pulmonary drug delivery devices, are used as permanent treatment or rescue therapy for respiratory diseases. As a result, they are gaining immense traction across the globe.
At present, healthcare practitioners and pulmonary diseases specialists are preferring a combination of a drug and a device on account of their fast and effective outcome. Furthermore, the expansion of chemical industries is resulting in the rising environmental pollution level and breathing problems, which, in turn, is driving the market. Additionally, the introduction of portable drug delivery devices is propelling the market growth.
2. What is the expected growth rate of the global COPD and asthma devices market during 2024-2032?
3. What are the key factors driving the global COPD and asthma devices market?
4. What has been the impact of COVID-19 on the global COPD and asthma devices market?
5. What is the breakup of the global COPD and asthma devices market based on the product?
6. What is the breakup of the global COPD and asthma devices market based on the indication?
7. What is the breakup of the global COPD and asthma devices market based on distribution channel?
8. What are the key regions in the global COPD and asthma devices market?
9. Who are the key players/companies in the global COPD and asthma devices market?
Chronic obstructive pulmonary disease (COPD) is an inflammatory disease that leads to obstructed airflow from the lungs. Its early symptoms include shortness of breath, wheezing, chest tightness, chronic cough with or without mucus, frequent cold, and throat soreness. On the other hand, asthma, also known as bronchial asthma, is a respiratory disorder that affects the airways in the lungs.
Its symptoms are shortness of breath, chest tightness, trouble sleeping, and coughing or wheezing attacks. These respiratory diseases are treated using various devices that help deliver inhaled medication. COPD and asthma devices, also known as pulmonary drug delivery devices, are used as permanent treatment or rescue therapy for respiratory diseases. As a result, they are gaining immense traction across the globe.
COPD and Asthma Devices Market Trends
The growing global geriatric population, which is highly susceptible to chronic respiratory disorders, represents one of the key factors positively influencing the market. In addition, rising occurrences of respiratory diseases caused due to the rising smoking of cigarettes are increasing the sales of COPD and asthma devices. Apart from this, the increasing expenditure on healthcare and continuous automation in the healthcare industry are contributing to the market growth. The widespread adoption of advanced medical solutions is offering lucrative growth opportunities to manufacturers across the globe.At present, healthcare practitioners and pulmonary diseases specialists are preferring a combination of a drug and a device on account of their fast and effective outcome. Furthermore, the expansion of chemical industries is resulting in the rising environmental pollution level and breathing problems, which, in turn, is driving the market. Additionally, the introduction of portable drug delivery devices is propelling the market growth.
Key Market Segmentation
This report provides an analysis of the key trends in each sub-segment of the global COPD and asthma devices market report, along with forecasts at the global, regional and country level from 2024-2032. The report has categorized the market based on product, indication and distribution channel.Breakup by Product:
- Inhalers
- Drug Powdered Inhalers (DPIs)
- Metered Dose Inhalers (MDIs)
- Soft Mist Inhalers
- Nebulizers
- Compressor Nebulizers
- Ultrasonic Nebulizers
- Mesh Nebulizers
Breakup by Indication:
- Asthma
- COPD
Breakup by Distribution Channel:
- Retail Pharmacies
- Hospitals
- Online Pharmacies
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players being Adherium Limited, Aristopharma Ltd., AstraZeneca PLC, Baxter International Inc., Boehringer Ingelheim International GmbH, Cohero Health Inc., Koninklijke Philips N.V., Omron Corporation, Pari Respiratory Equipment Inc., Recipharm AB and Verona Pharma plc.Key Questions Answered in This Report
1. What was the size of the global COPD and asthma devices market in 2023?2. What is the expected growth rate of the global COPD and asthma devices market during 2024-2032?
3. What are the key factors driving the global COPD and asthma devices market?
4. What has been the impact of COVID-19 on the global COPD and asthma devices market?
5. What is the breakup of the global COPD and asthma devices market based on the product?
6. What is the breakup of the global COPD and asthma devices market based on the indication?
7. What is the breakup of the global COPD and asthma devices market based on distribution channel?
8. What are the key regions in the global COPD and asthma devices market?
9. Who are the key players/companies in the global COPD and asthma devices market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global COPD and Asthma Devices Market
6 Market Breakup by Product
7 Market Breakup by Indication
8 Market Breakup by Distribution Channel
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Adherium Limited
- Aristopharma Ltd.
- AstraZeneca PLC
- Baxter International Inc.
- Boehringer Ingelheim International GmbH
- Cohero Health Inc.
- Koninklijke Philips N.V.
- Omron Corporation
- Pari Respiratory Equipment Inc.
- Recipharm AB
- Verona Pharma plc
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 137 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 45.7 Billion |
| Forecasted Market Value ( USD | $ 69.5 Billion |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
